CA Stock MarketDetailed Quotes

BIOV BioVaxys Technology Corp

Watchlist
  • 0.040
  • 0.0000.00%
15min DelayMarket Closed Apr 24 15:55 ET
11.66MMarket Cap-2.00P/E (TTM)

About BioVaxys Technology Corp Company

BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.

Company Profile

SymbolBIOV
Company NameBioVaxys Technology Corp
Founded2018
MarketCNQ
Employees6
Fiscal Year Ends10-31
Address595 Howe Street Suite 303
CityVancouver
CountryCAN
Zip CodeV6C 2T5
Phone+1 740 358-0555

Company Executives

  • Name
  • Position
  • Salary
  • James Passin
  • Chief Executive Officer and Director
  • --
  • David Wang
  • Director
  • --

Market Insights

Warren Buffett Portfolio Warren Buffett Portfolio

Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.

Unlock Now

Discussing

2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current Show More